Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages

作者：Da-Long Yang, Lin Ye, Fan-Jian Zeng, Jie Liu, Hongbing Yao, Jun-Liang Nong, Shaoping Liu, Ning Peng, Wenfeng Li, Pei‐Sheng Wu, Chuang Qin, Ze Su, Jun‐Jie Ou, Xiaofeng Dong, Yi-He Yan, Teng-Meng Zhong, X H Mao, Ming-Song Wu, Yao-Zhi Chen, Guo-Dong Wang, Mian-Jing Li, Xueyao Wang, Fuquan Yang, Yong-Rong Liang, Shuchang Chen, Yong‐Yu Yang, Kang Chen, Fu-Xin Li, Yongrong Lai, Qingqing Pang, Xiumei Liang, Xue‐Mei You, Bang‐De Xiang, Yaqun Yu, Liang Ma, Jian‐Hong Zhong, on behalf of the GUIDANCE investigators · 发表于：Hepatology · 年份：2025 · DOI：10.1097/hep.0000000000001401 · 被引用次数：4 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver Disease Diagnosis and Treatment、Liver physiology and pathology

In the original article by Yang et al,1 an error was inadvertently introduced in Table 2. Under the disease control rate, the value of TACE alone, under the Modified RECIST criteria, was mistakenly written as 259 (56.6). It should be 259 (56.4). Table 2 has been updated accordingly in this issue.